Stemtech Announces China Market Expansion
Stemtech Unveils Bold Vision ‘Grand China Market Plan' to Supercharge China's Thriving Health and Wellness Landscape Amidst $ 683 Billion...
Stemtech Unveils Bold Vision ‘Grand China Market Plan' to Supercharge China's Thriving Health and Wellness Landscape Amidst $ 683 Billion...
Net revenue increased 36% in Q2 2023 versus Q1 2023Top line results expected late October 2023 for company's phase 3...
Combination study of SON-1010 with Roche's atezolizumab (Tecentriq®) has been initiated in AustraliaFirst SON-1010 Phase 1 study has been completed...
Continued rapid pace of enrollment with ~75% of expected patients now enrolled in ongoing potentially pivotal study evaluating Berubicin for...
LOS ANGELES, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Solve GNE announced today that it has entered into a sponsored research...
MSLs can now leverage the power of HCP Universe anywhere, at any time to enhance interactions with healthcare leadersNEW YORK,...
Renowned scientist will advise on the development of IMUNON’s FixPlas and IndiPlas modalities in immuno-oncology LAWRENCEVILLE, N.J., Aug. 14, 2023...
Earl Douglas General Counsel, Allogene TherapeuticsSOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO),...
YONKERS, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery...
JENKINTOWN, Pa., Aug. 14, 2023 (GLOBE NEWSWIRE) -- SFA Therapeutics, a clinical-stage biotech using a first-in-class immuno-modulation technology platform, announced positive...
Announced today that all 3 patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment...
Patent developed in collaboration with Syngene International Ltd.MINNEAPOLIS, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a...
Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024...
CORAL GABLES, Fla., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company...
Rapidly advancing clinical pipeline across multiple high-value inflammatory, fibrotic and autoimmune diseases On track to launch a Phase 2a biomarker...
Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010, an investigational ophthalmic formulation of bevacizumab...
MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing...
Reported statistically significant reductions in plasma neurofilament light chain (NfL) levels compared to placebo at 24 weeks (p=0.04) in patients...
Merger with Notable expected to close in late September or October, subject to VBL’s S-4 registration statement being declared effective...
Highlights AHI enters a second commercial agreement in the UAE.IntelliGen Founders have worked with, and within the Government, Healthcare needs...